8 results about "Papilloma virus" patented technology

Multiantigenic human papillomavirus (HPV) molecular vaccine constructs for use and treatment of HPV-related disorders and conditions, e.g., HPV molecular vaccines targeting HPV6 and HPV11-associated recurrent respiratory papillomatosis (RRP).

This invention relates to antisense oligonucleotides targeting different subtypes of human papillomavirus (HPV) oncogenes and their applications. The ASO molecules are 14–40 bases in length and specifically pair with specific regions of target genes. This invention also relates to the following applications of the ASO molecules: (1) preparing preparations to inhibit HPV virus expression; or (2) preparing drugs or drug compositions for treating diseases related to HPV infection; or (3) treating diseases related to HPV infection; or (4) inhibiting the expression of HPV virus genes.

The application discloses a urine papillomavirus rapid self-checking kit. The application provides a self-made composite magnetic bead, the magnetic bead has high DNA affinity, can rapidly enrich free DNA (cfDNA) in urine, and can detect 6 copies of HPV virus in each reaction by combining a CRISPR technology. The kit provided by the application is roughly divided into the following operation steps: collecting urine, mixing the sample, magnetic bead adsorption, resuspension and amplification of the sample, and the results show five steps. The whole operation is only needed to be carried out in an environment of about 37 DEG C, and the detection of each sample only needs less than 30 min, without the need of expensive equipment and professional personnel, and thus the home self-checking is truly realized.

This invention discloses the use of sulfonated chitosan in inhibiting human papillomavirus (HPV) infection. The sulfonated chitosan of this invention can inhibit HPV infection of cells in vitro and is non-toxic to cells, thus having the use in preventing or treating HPV infection and related diseases, especially cervical cancer and condyloma acuminata.

This invention discloses a traditional Chinese medicine composition for treating human papillomavirus (HPV) infection, its preparation method, and its application. The composition is made from multiple traditional Chinese medicines, including Polygonum cuspidatum, Polygonatum sibiricum, and Atractylodes macrocephala (fried), in a specific weight ratio. Through processes such as decoction extraction, concentration, and granulation, the composition can be prepared into various pharmaceutically acceptable dosage forms, including decoctions, granules, tablets, capsules, pills, powders, and oral liquids. The traditional Chinese medicine composition of this invention has the effects of "tonifying qi and kidneys, detoxifying and removing dampness, and supporting the body's resistance to pathogens," and can be effectively used to treat human papillomavirus (HPV) infection. The preparation process of this invention is simple, and the efficacy is definite, providing a new medication option for the clinical treatment of HPV infection.

The present disclosure provides, among other things, a pharmaceutical composition that includes a lipid nanoparticle adjuvant and an anti-human papillomavirus (HPV) comprising HPV virus-like particles (VLPs) of at least one type of human papillomavirus (HPV) selected from the group consisting of HPV types: 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 55, 56, 58, 59, 66, 68, 73, and 82.

Multiantigenic human papillomavirus (HPV) molecular vaccine constructs for use and treatment of HPV-related disorders and conditions, e.g., HPV molecular vaccines targeting HPV16, HPV18, and HPV-45-related conditions.

The present invention regards a combination or composition including epigallocatechin gallate (EGCG) and at least one other agent selected from folic acid, vitamin B12 and low or very low molecular weight hyaluronic acid (1-500 kDa), or derivatives, for the prevention, the control, and the treatment of a human papillomavirus infection in a subject.